Neumora Therapeutics, Inc.
NMRA
Positions held
Your positionsNMRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $90.15M | Enterprise value | $26.57M | Trailing P/E | — | Forward P/E | -0.72 |
| PEG | — | Price / book | 2.02 | Beta | 2.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.9% | ROA | -73.9% | Debt / equity | 1.20 |
| Current ratio | 4.50 | Free cash flow | -$99.42M | Analyst recommendation | none | Mean target | $6.14 |
| 52w high | $3.65 | 52w low | $0.45 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$43.1M | -$53.5M | -$59.5M | -$56.8M | -$52.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.2M | -$52.9M | -$58.5M | -$57.7M | -$54.0M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$237M | -$244M | -$236M | -$131M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$241M | -$263M | -$252M | -$136M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-18 · Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-04 · ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
2026-08-14 · Neumora Therapeutics Promotes Joshua Pinto to CEO; Names New Chief Medical Officer
2026-08-14 · Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-27 · Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study
2026-07-27 · Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
2026-07-13 · RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk
2026-07-11 · Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
Price (daily)
Full chart · RSI · MACD · patterns